Tarsus Pharmaceuticals, Inc. is a biopharmaceutical company, which is focused on the development and commercialization of therapeutics. The Company’s lead product candidate, TP-03, is an investigational eye drop in Phase III to treat blepharitis caused by the infestation of Demodex mites, which is referred to as Demodex blepharitis. Blepharitis (Blephar is a reference to eyelid and itis is a reference to inflammation) is a condition characterized by inflammation of the eyelid margin, redness and ocular irritation, including a specific type of eyelash dandruff called collarettes, which are pathognomonic for Demodex blepharitis. The Company designed TP-03 to target and eradicate the root cause of Demodex blepharitis, Demodex mite infestation. The active pharmaceutical ingredient (API) of TP-03, lotilaner, paralyzes and eradicates mites and other parasites through the inhibition of parasite-specific gamma-aminobutyric acid-gated chloride (GABA-Cl) channels.